Longeveron Reports Q2 2026 Financial Results with Revenue Decline and Increased Net Loss

Longeveron Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $287,000, a decrease of 10% from $316,000 in the same period last year. The decline was primarily attributed to the absence of contract manufacturing revenue, which fell to zero from $18,000 in the prior year. Clinical trial revenue, derived from The Bahamas Registry Trial, remained stable at $287,000. The company incurred a net loss of $6.1 million for the quarter, compared to a loss of $5.0 million in the second quarter of 2025, reflecting increased operating expenses.

For the first half of 2026, Longeveron reported total revenues of $685,000, a slight decrease from $697,000 in the same period of 2025. The company’s gross profit for the six months was $446,000, unchanged from the previous year. Operating expenses rose to $11.4 million from $11.0 million, driven by higher general and administrative costs, which increased by 7% to $5.9 million, and research and development expenses, which were relatively flat at $5.5 million. The accumulated deficit as of June 30, 2026, stood at $143.1 million.

In terms of strategic developments, Longeveron completed a private placement in March 2026, raising approximately $15.9 million in gross proceeds. This financing included the issuance of Class A common stock and Series A preferred stock, as well as warrants. The company also has access to an At-The-Market (ATM) equity financing vehicle, allowing for the potential sale of up to $10.7 million in shares, although restrictions apply based on stock price conditions.

Operationally, Longeveron is advancing its lead investigational product candidate, laromestrocel, through clinical trials for several indications, including Hypoplastic Left Heart Syndrome (HLHS) and Alzheimer’s disease. The ongoing ELPIS II trial for HLHS is fully enrolled, with top-line results expected in September 2026. The company has also received Small or Medium-sized Enterprise (SME) status from the European Medicines Agency, which may facilitate its regulatory processes in Europe.

Looking ahead, Longeveron anticipates continued operating losses and recognizes the need for additional capital to fund its operations. The company expects its existing cash and cash equivalents, totaling $10.1 million as of June 30, 2026, will be sufficient to support operations into the fourth quarter of 2026. However, it acknowledges substantial doubt about its ability to continue as a going concern without securing further financing. The company plans to pursue additional capital through various means, including equity offerings and strategic partnerships, to support its ongoing clinical development and operational needs.